Related Experiment Videos
Additional molsidomine in refractory unstable angina pectoris.
Cardiovascular Drugs and Therapy
|May 1, 1988
Summary
Molsidomine effectively stabilized unstable angina in most patients refractory to standard therapies. This study highlights its potential as an add-on treatment for refractory angina.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Unstable angina is a critical condition often refractory to conventional triple therapy.
- Patients with refractory angina may have limited treatment options, including surgical or interventional procedures.
Purpose of the Study:
- To evaluate the efficacy and safety of additional molsidomine in patients with unstable angina unresponsive to triple therapy.
- To assess molsidomine's role in managing refractory angina when other treatments fail or are not feasible.
Main Methods:
- Prospective, single-blind study involving 20 patients with unstable angina.
- Patients received oral molsidomine (12-24 mg/day), with initial intravenous administration in 15 patients.
- Coronary artery disease was documented in 17 patients; 2 had severe coronary spasms.
Main Results:
- Molsidomine stabilized unstable angina in 13 of 20 patients, eliminating resting angina.
- Five patients experienced a marked reduction in anginal attack frequency.
- No severe adverse effects were reported; five patients experienced moderate headaches.
Conclusions:
- Molsidomine demonstrates significant efficacy in stabilizing unstable angina refractory to standard treatments.
- It offers a viable therapeutic option for patients with limited surgical or interventional possibilities.
- Molsidomine is generally well-tolerated, with mild headaches as the most common side effect.